Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Provides Corporate Update Related to COVID-19 Pandemic
YAVNE, Israel , March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19
View HTML
Toggle Summary BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid Deployment
Total non-dilutive funds for NexoBrid now valued at over $200 million YAVNE, Israel , March 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today
View HTML
Toggle Summary MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
YAVNE, Israel , Feb. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , MediWound’s Chief Executive Officer, will
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
Generated total full-year 2019 revenues of $31.8 million , driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers BARDA initiated the procurement of NexoBrid valued at $16.5
View HTML
Toggle Summary MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
YAVNE, Israel , Feb. 18, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
YAVNE, Israel , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agreement with GENFA MEDICA SA , granting it
View HTML
Toggle Summary BARDA Initiates the Procurement of NexoBrid for Emergency Response
YAVNE, Israel and CAMBRIDGE, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for
View HTML
Toggle Summary MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical
YAVNE, Israel , Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the signing of a distribution agreement granting Balance Medical
View HTML
Toggle Summary MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
Interim assessment anticipated by end of 2020 YAVNE, Israel , Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the
View HTML
Toggle Summary MediWound Reports Third Quarter 2019 Financial Results
Total revenues of $5.1 million , driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020 Expected to initiate patient treatment in EscharEx® U.S.
View HTML